Merus NV

$22.64 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Join the waitlist

About Merus NV

Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

Stock Analysis

last close $23.29
1-mo return 2.8%
3-mo return 12.3%
avg daily vol. 170.84T
52-week high 31.27
52-week low 10.18
market cap. $823M
forward pe -
annual div. -
roe -73.2%
ltg forecast -
dividend yield -
annual rev. $30M
inst own. 69.6%

Join the waitlist for early access and a chance to earn $50 in free stock

Join the waitlist